

Touch Tears

TOUCH tears glucose offers diabetic patients a game changing technology to self-monitor their glucose levels without the painful finger pricks!



PROBLEM

CURRENTLY DIABETIC PATIENTS CAN ONLY USE PAINFUL FINGER PRICKS TO SELF-MONITOR THEIR GLUCOSE LEVELS. THIS LEADS TO A LARGE MAJORITY OF THE PATIENTS TO BE NONCOMPLIANT. TYPICALLY A DOCTOR REQUESTS 2-10 TIMES OF TESTING DAILY, HOWEVER, THE NATIONAL AVERAGE THAT PEOPLE ACTUALLY COMPLY WITH IS UNDER 2. NONCOMPLIANCE LEADS TO FUTURE COMPLICATIONS THAT ARE A LARGE BURDEN ON THE HEALTHCARE SYSTEM. FURTHERMORE:

- 25 MIL IN THE US ARE DIAGNOSED AS EITHER TYPE I, II OR GESTATIONAL
 - 285 MIL PEOPLE WORLDWIDE
 - THESE NUMBERS ARE PASSING EXPECTATIONS YEARLY BUT ARE EXPECTED TO TRIPLE BY 2030
 - COMPLICATIONS WITH THE DISEASE ACCOUNT FOR SOME \$471 BILLION IN ASSOCIATED HEALTH CARE COST IN THE US ALONE FOR 2010
 - THERE IS POOR COMPLIANCE
 - A MAJOR ISSUE WITH LANCET REUSE
 - ALTERNATIVE SITE TESTING STILL OFFERS LITTLE HOPE
 - NO ALTERNATIVE TECHNOLOGY APPROVED BY THE FDA
- THERE HAS BEEN NO ALTERNATIVE TECHNOLOGY DRIVEN TO MARKET DIRECTLY MEASURING GLUCOSE LEVELS UNTIL TOUCH TEARS GLUCOSE.

TOUCH SOLUTION

OUR TOUCH SENSOR USES TEAR FLUID AS THE MEDIUM, THEREFORE NO PAINFUL FINGER PRICKS ARE REQUIRED AND NO LANCETS AND ALCOHOL WIPES EITHER. THE TEAR CAPTURE SYSTEM AND SENSOR ARE INTEGRATED, PROVIDE FOR NO SAMPLE EVAPORATION AND QUICK AND RELIABLE TEAR GLUCOSE CORRELATION TO BLOOD GLUCOSE.

LUCRATIVE MARKET

CURRENTLY THE SELF MONITORING BLOOD GLUCOSE MARKET IS COMPRISED OF FIVE MAJOR COMPANIES AND ACCOUNTS FOR \$9 BILLION ANNUALLY IN SALES OF JUST THE TEST STRIPS. THIS \$9 BILLION FIGURE ONLY ACCOUNTS FOR THE LESS THAN 2 TIMES PER DAY THAT THE DIABETIC ACTUALLY TESTS, IF COMPLIANCE COULD BE BROUGHT UP TO THE 3-10 TIMES PER DAY RECOMMENDED FIGURE, THIS NUMBER WOULD INCREASE AS WELL.

READY TO GROW

TOUCH IS IN ITS PIVOTAL TESTING PHASE. WE HAVE PERFORMED MUCH OF THE BENCH TOP STUDIES. CURRENTLY WE ARE COMPLETING THE PILOT ANIMAL STUDIES TO SHOW CORRELATION BETWEEN TEAR AND BLOOD GLUCOSE AND DISTINGUISH THE TIME DIFFERENCE BETWEEN THE TWO AS WELL.

EXPERT BIOMEDICAL ENGINEER

THE INVENTING ENGINEERS AT TOUCH HOLD PATENTS AND NUMEROUS PUBLICATIONS AND 20+ YEARS OF MEDICAL DEVICE DESIGN AND A CLOSE CLINICAL RELATIONSHIP WITH MAYO CLINIC AZ.

CRITICAL PATH TO SUCCESS

THE TEAM IS DEVELOPING THE NEXT STAGES TO SUCCESSFULLY BREAK INTO THE DIABETES MANAGEMENT MARKET. TO FURTHER PUSH THIS TECHNOLOGY, LIMITED PATIENT STUDIES FOR ERGONOMICS, SAFETY, CORRELATION, LAG TIME OF TEAR TO BLOOD GLUCOSE, MASS FABRICATION, AND A LARGER POPULATION STUDY STILL REMAIN. WITH THE CORRECT PARTNERS IN LINE FROM BIOACCEL, MAYO CLINIC AND ASU, TOUCH TEARS GLUCOSE WILL BE AN ALTERNATIVE TO DIABETICS SOON.